Intravenous Alpha Lipoic Acid (ALA) Protocols for Diabetic Neuropathy
A summary of evidence-based human clinical trials covering dosing, frequency, duration, and measurable outcomes.
The Case for Intravenous Delivery
Alpha lipoic acid (ALA), also known as thioctic acid, is a mitochondrial antioxidant with well-documented neuroprotective and metabolic properties. When administered intravenously, it achieves plasma levels far exceeding oral supplementation, enabling direct modulation of oxidative stress and nerve function.
At Blue Mountain Wellness, IV therapy is one of the tools we use as part of a comprehensive, personalized neuropathy protocol, alongside targeted nutrition, red light therapy, and functional medicine.
The following parameters represent the most robustly studied and replicated IV ALA protocol across major randomized controlled trials. Doses above 600 mg/day have not demonstrated added efficacy but do increase adverse events.
Key Clinical Trials
Measurable Outcome Instruments
| Instrument | What It Measures | Scale / Range | Used In |
|---|---|---|---|
| Total Symptom Score (TSS) | Pain, burning, paresthesia, numbness in feet | 0–14.64 (lower = better) | ALADIN, SYDNEY, ALADIN III |
| Neuropathy Impairment Score (NIS / NIS-LL) | Motor and sensory deficits on clinical exam | 0–88 (lower = better) | ALADIN III, Cochrane review |
| Nerve Conduction Velocity (NCV) | Objective electrophysiological nerve function | m/s (higher = better) | Systematic review (15 RCTs) |
| Hamburg Pain Adjective List | Multidimensional pain quality characterization | Composite scale | ALADIN |
| Neuropathy Symptoms & Change (NSC) Score | Patient-reported functional and symptom change | Composite score | SYDNEY 2 (oral) |
| Visual Analog Scale (VAS) | Subjective pain intensity | 0–10 (lower = better) | Pregabalin + ALA trial (2026) |
Meta-Analytic Conclusions
Quick Summary
| Parameter | Evidence-Based Standard | Notes |
|---|---|---|
| Dose | 600 mg IV | Optimal risk-to-benefit ratio; 300 mg used in some protocols |
| Frequency | Once daily | Weekday dosing common in outpatient settings |
| Duration | 3 weeks (15–21 sessions) | Minimum efficacy seen at 2 weeks (SYDNEY) |
| Infusion Time | 30–60 minutes | Slower infusion reduces nausea risk |
| Maintenance | Oral ALA 600 mg/day | Evidence weaker than IV; consider for long-term antioxidant support |
| Monitoring | Blood glucose · infusion site · vitals | Hypoglycemia risk in diabetics; monitor closely |
| Contraindicated | Doses >600 mg/day IV not recommended | No added benefit; dose-dependent nausea, vomiting, vertigo |
We Offer IV Therapy for Neuropathy
At Blue Mountain Wellness, IV ALA therapy is integrated into our comprehensive neuropathy reversal program, alongside red light therapy, targeted nutrition, and personalized functional medicine protocols. If you are ready to address the root cause of your nerve symptoms, we are here to help.